Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

Verve Therapeutics, Inc.’s VERV share price has dipped by 11.69%, which has investors questioning if this is right time to buy.

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Serina Therapeutics Background Information (This description ... targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in ...

Anthony Bergmann; Chief Financial Officer; Capricor Therapeutics Inc. Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc. Edward T ...

Lorundrostat demonstrated strong efficacy and safety in the pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. These ...

3 Reasons Investors Watch United Therapeutics (UTHR) Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% ...

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Check Out Our Latest Analysis on United Therapeutics United Therapeutics Stock Down 1.6 % UTHR stock opened at $313.60 on Wednesday. United Therapeutics has a 52-week low of $221.53 and a 52-week ...

United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million.

United Therapeutics is rated as a BUY due to high financial growth, positive long-term outlook, and current undervaluation despite patent expiration concerns. The company’s revenue is heavily ...